Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.33 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TYMP | P19971 | 1/20 | 0.32 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18420648 | 0.77 | MEN1 (0.40) | GALR3MAPTKDM4EGPR35TSHR | |
| SCHEMBL28341704 | 0.72 | MAPT (0.38) | GALR3MAPTKDM4ETSHRKMT2A | |
| SCHEMBL2894527 | 0.71 | MAPT (0.40) | GALR3MAPTKDM4ETYMPAR | |
| SCHEMBL2760496 | 0.71 | HCAR2 (0.35) | GALR3MAPTKDM4EGPR35ALDH1A1 | |
| SCHEMBL28880802 | 0.70 | MAPT (0.37) | GALR3MAPTKDM4ETSHRKMT2A | |
| SCHEMBL6788951 | 0.67 | TYMP (0.32) | TYMPARALDH1A1KMT2A | |
| SCHEMBL8789178 | 0.64 | HCAR2 (0.30) | TYMPKMT2A | |
| SCHEMBL17057787 | 0.63 | GRIN2D (0.37) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31469646 | 0.63 | GRIN2D (0.48) | GALR3GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29076355 | 0.62 | PIM1 (0.32) | GALR3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220169654-A1 | New Organic Compounds | SERVIER PHARMACEUTICALS LLC (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2022115521-A1 | (HETEO)ARYL SUBSTITUTED PYRROLO-, PYRAZOLO- AND TRIAZOLOPYRIDAZINE DERIVATES AS MAT2A INHIBITORS | SERVIER PHARMACEUTICALS, LLC (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-2137179-B1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2586778-A2 | Pyridazinone derivatives useful as glucan synthase inhibitors | Merck Sharp & Dohme Corp. (US) | 2013-05-01 | — | — | EP | disclosed |
| WO-2013004984-A1 | TRICYCLIC COMPOUNDS FOR USE AS KINASE INHIBITORS | CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) | 2013-01-10 | — | — | WO | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-8232274-B2 | Pyridazinone derivatives useful as glucan synthase inhibitors | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. | 2009-07-02 | — | — | US | disclosed |
| WO-2008115381-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-2005077915-A1 | PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | WO | disclosed |
| EP-0275997-B1 | 3(2H)PYRIDAZINONE, PROCESS FOR ITS PREPARATION AND ANTAGONISTIC AGENT AGAINST SRS-A CONTAINING IT | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-12-23 | — | — | EP | disclosed |
| US-5011839-A | Antagonists to slow reacting substance of anaphylaxis | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1991-04-30 | — | — | US | disclosed |
| US-4978665-A | ANTIALLERGENS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-12-18 | — | — | US | disclosed |
| EP-0376079-A1 | 3(2H)pyridazinones, processes for their preparation and antagonistic agent against SRS-A | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1990-07-04 | — | — | EP | disclosed |
| EP-0275997-A1 | 3(2H)pyridazinone, process for its preparation and antagonistic agent against SRS-A containing it | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1988-07-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170861-A1 | Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors | MAN2A1, GYS2, MANBA | GALR3 1870/4885GRIN2D 4444/4885GRIN3B 3538/4885 |
| US-20220169654-A1 | New Organic Compounds | MNAT1, MAT2A, EIF4A2 | GALR3 2143/4885GRIN2D 463/4885GRIN3B 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.